Wyeth Investors Likely To Win Class Cert. In Pristiq Case

Law360, New York (May 10, 2012, 9:35 PM EDT) -- A New York federal judge on Thursday said he will likely grant class certification to a group of investors who claim Pfizer Inc. unit Wyeth Pharmaceuticals Inc. did not disclose serious side effects associated with the antidepressant Pristiq.

Investors led by a pipe fitters union have asked to go forward as a class in a suit claiming Wyeth, then an independent company, committed securities fraud by failing to disclose heart- and liver-related side effects that appeared during Pristiq's clinical trials.

“I'm going to reserve [judgment] but...
To view the full article, register now.